Biocartis Group NV (BIOGF)

USD 0.66

(-85.33%)

Market Cap (In USD)

65.4 Million

Revenue (In USD)

57.48 Million

Net Income (In USD)

-65.38 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.66-0.66
PE
-
EPS
-
Beta Value
1.386
ISIN
BE0974281132
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Roger Moody
Employee Count
-
Website
https://www.biocartis.com
Ipo Date
2021-10-14
Details
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.